08:15 AM EDT, 06/27/2025 (MT Newswires) -- Allarity Therapeutics ( ALLR ) said Friday it has dosed a second patient in a new phase 2 clinical trial evaluating stenoparib in patients with advanced ovarian cancer.

The company said the new trial builds on earlier phase 2 data showing that twice-daily dosing of stenoparib had durable clinical benefit and favorable tolerability.

Allarity shares were up over 3% in recent premarket activity.